Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:36:27.694Z.
Consensus retrieved: 2026-10-06T10:38:11.526Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:36:27.694Z.
Quote observation: 2026-10-06T16:34:27.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 80308b770ced1bdfd1e00e86669fc95a739831df2c659c0b91f47c7a41a76c0c
Forward PE Ratio (N/A) = Dated Quote Price ($23.62) / Consensus Forward EPS ($-25.01)
FORWARD PE RATIO
N/A
Cue Biopharma, Inc.
Market Cap
$171.59M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Cue Biopharma, Inc. (CUE) | $171.59M | N/A |
| Organogenesis Holdings Inc. (ORGO)vs › | $171.14M | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $172.71M | N/A |
| Nkarta, Inc. (NKTX)vs › | $170.28M | N/A |
| MediWound Ltd. (MDWD)vs › | $169.88M | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $173.75M | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $174.15M | N/A |
| OptimizeRx Corp. (OPRX)vs › | $166.73M | 9.91 |
| Journey Medical Corporation (DERM)vs › | $177.81M | N/A |
| Quanterix Corporation (QTRX)vs › | $163.22M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $23.62, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-25.01 | $-35.22 – $-17.60 | 2 | n/m |
| 2027-12-31 | $-7.44 | $-10.48 – $-5.24 | 2 | n/m |
| 2028-12-31 | $-6.71 | $-8.27 – $-5.16 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
